ECSP10010631A - Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer - Google Patents

Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer

Info

Publication number
ECSP10010631A
ECSP10010631A EC2010010631A ECSP10010631A ECSP10010631A EC SP10010631 A ECSP10010631 A EC SP10010631A EC 2010010631 A EC2010010631 A EC 2010010631A EC SP10010631 A ECSP10010631 A EC SP10010631A EC SP10010631 A ECSP10010631 A EC SP10010631A
Authority
EC
Ecuador
Prior art keywords
methods
release factor
cancer treatment
corticotropine
corticotropine release
Prior art date
Application number
EC2010010631A
Other languages
English (en)
Inventor
Stephen Evans-Freke
Original Assignee
Neutron Row
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Row filed Critical Neutron Row
Publication of ECSP10010631A publication Critical patent/ECSP10010631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Resumen Se determina en la presente un método para tratar cáncer en un ser humano administrando una alta dosis del factor de liberación de corticotropina (CRF) durante un periodo de tiempo que excede 3 días.
EC2010010631A 2008-04-30 2010-11-24 Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer ECSP10010631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US9480608P 2008-09-05 2008-09-05

Publications (1)

Publication Number Publication Date
ECSP10010631A true ECSP10010631A (es) 2011-02-28

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010631A ECSP10010631A (es) 2008-04-30 2010-11-24 Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer

Country Status (17)

Country Link
US (1) US20100113341A1 (es)
EP (1) EP2259793A2 (es)
JP (1) JP2011519375A (es)
KR (1) KR20110021820A (es)
CN (1) CN102036680A (es)
AU (1) AU2009241813A1 (es)
CA (1) CA2722426A1 (es)
CO (1) CO6300959A2 (es)
CR (1) CR11762A (es)
EC (1) ECSP10010631A (es)
IL (1) IL209005A0 (es)
MX (1) MX2010011882A (es)
NI (1) NI201000185A (es)
NZ (1) NZ588877A (es)
RU (1) RU2010148803A (es)
WO (1) WO2009134396A2 (es)
ZA (1) ZA201007729B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
RU2012102259A (ru) * 2009-06-24 2013-07-27 Стефен ЭВАНС-ФРИК Способы применения кортикотропин-рилизинг фактора для лечения рака

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
US4533654A (en) * 1982-09-29 1985-08-06 The Salk Institute For Biological Studies Urotensin peptides
US4528189A (en) * 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子－12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
EP1761281A1 (en) * 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
RU2010148803A (ru) 2012-06-10
KR20110021820A (ko) 2011-03-04
EP2259793A2 (en) 2010-12-15
NZ588877A (en) 2012-08-31
AU2009241813A1 (en) 2009-11-05
MX2010011882A (es) 2011-02-25
NI201000185A (es) 2013-04-22
CN102036680A (zh) 2011-04-27
US20100113341A1 (en) 2010-05-06
CR11762A (es) 2011-04-26
ZA201007729B (en) 2014-02-26
WO2009134396A2 (en) 2009-11-05
CO6300959A2 (es) 2011-07-21
CA2722426A1 (en) 2009-11-05
JP2011519375A (ja) 2011-07-07
WO2009134396A3 (en) 2010-04-15
IL209005A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
MX2020009773A (es) Terapia de combinacion.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
MX2020001727A (es) Terapia de combinacion.
PH12013500857A1 (en) Methods and compositions for treating hiv-associated diarrhea
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
BR112023019156A2 (pt) Inalador pressurizado dosimetrado e formulação para uso em um método para tratar uma reação alérgica aguda
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
ECSP10010631A (es) Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer
MX2021001764A (es) Terapia de combinacion.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
NO20064754L (no) Kombinasjonsterapi
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
UA102098C2 (ru) Применение кортикотропин-рилизинг фактора для лечения рака